The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA

News detail

Return to all news & events

06/10/2017 Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA

Physiogenex has investigated the acute effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption in the Golden Syrian hamster model.

Dr. François Briand, Director of Research and Business Development at Physiogenex, will present the study results during the 77th American Diabetes Association 2017 scientific sessions in San Diego, CA, USA.

The oral presentation is scheduled during the oral abstract session (Lipid modifying interventions and their consequences AC-OR07, abstract#229) from 6:00pm-6:15am on Sunday, June the 11th, 2017.

Check the abstract on ADA 2017 website

If you wish to know more about running preclinical experiments with us, ask Physiogenex experts

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information